NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT05945823 2025-12-29Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsTaiho Oncology, Inc.Phase 2 Active not recruiting53 enrolled
NCT04956640 2025-09-25Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Eli Lilly and CompanyPhase 1/2 Recruiting540 enrolled
NCT04953962 2023-08-15Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic CancerCanBas Co. Ltd.Phase 2 Completed36 enrolled
NCT00101907 2014-03-20Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced CancerAmgenPhase 1 Terminated41 enrolled 17 charts